SCHEDULE 13G: Adage Capital Management Discloses 5.32% Stake in Ensysce Biosciences

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 5.32% in Ensysce Biosciences, Inc.'s common stock.

Summary

• Adage Capital Management, L.P., a Delaware limited partnership, has filed a Schedule 13G indicating beneficial ownership in Ensysce Biosciences, Inc.
• Robert Atchinson and Phillip Gross, as managing members of entities related to Adage Capital Management, are also listed as reporting persons.
• The reporting persons collectively beneficially own 74,711 shares of Ensysce Biosciences, Inc. Common Stock.
• This ownership represents 5.32% of the company's outstanding Common Stock.
• The percentage is calculated based on 1,405,134 shares of Common Stock outstanding as of March 7, 2025, as reported in the company's Annual Report on Form 10-K.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently conveys positive or negative sentiment regarding the company's performance or outlook. The sentiment is neutral.

Positives

• The disclosure of a significant stake by an institutional investor like Adage Capital Management may signal confidence in Ensysce Biosciences, Inc. from a notable investment firm.

Risks

• The filing itself does not detail specific risks related to Ensysce Biosciences, Inc.'s operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded biotechnology or pharmaceutical company. Such disclosures are common and reflect investment decisions rather than operational updates. The specific impact on Ensysce Biosciences, Inc. within the broader industry context would depend on the market's interpretation of Adage Capital Management's investment strategy and the company's ongoing developments.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like Adage Capital Management could be viewed positively, potentially increasing investor confidence and demand for the stock.
• Company Management: Awareness of a new significant institutional shareholder may influence management's communication and strategic considerations, though the filing explicitly states the stake is not for control purposes.

Key Dates

Keywords

Ensysce Biosciences Inc., Adage Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management, Robert Atchinson, Phillip Gross